117 related articles for article (PubMed ID: 37909949)
1. Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
Matsunaga T; Satio H; Sakano YU; Makinoya M; Shimizu S; Shishido Y; Miyatani K; Kono Y; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
Anticancer Res; 2023 Nov; 43(11):5051-5059. PubMed ID: 37909949
[TBL] [Abstract][Full Text] [Related]
2. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
3. Impact of skeletal muscle mass in patients with recurrent gastric cancer.
Matsunaga T; Satio H; Miyauchi W; Shishido Y; Miyatani K; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
World J Surg Oncol; 2021 Jun; 19(1):170. PubMed ID: 34116681
[TBL] [Abstract][Full Text] [Related]
4. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
5. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
6. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
7. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
9. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
Amitani M; Oba T; Kiyosawa N; Morikawa H; Chino T; Soma A; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Maeno K; Ito KI
BMC Cancer; 2022 Mar; 22(1):327. PubMed ID: 35346102
[TBL] [Abstract][Full Text] [Related]
11. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study.
Nozawa H; Emoto S; Murono K; Shuno Y; Kawai K; Sasaki K; Sonoda H; Ishii H; Iida Y; Yokoyama Y; Anzai H; Ishihara S
Therap Adv Gastroenterol; 2020; 13():1756284820971197. PubMed ID: 33240393
[TBL] [Abstract][Full Text] [Related]
12. Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment.
Zurlo V; Rosa F; Rinninella E; Pontolillo L; Beccia V; Maratta M; Tortora G; Alfieri S; Pozzo C; Strippoli A
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1575-1584. PubMed ID: 38436190
[TBL] [Abstract][Full Text] [Related]
13. Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses.
da Rocha DS; Tessari JA; Mainardi NB; Hax V; Gasparin AA; de Oliveira CAV; Garcia TS; Xavier RM; Chakr RMDS
Semin Arthritis Rheum; 2023 Apr; 59():152168. PubMed ID: 36736023
[TBL] [Abstract][Full Text] [Related]
14. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
17. Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer.
Nishigori T; Tsunoda S; Obama K; Hisamori S; Hashimoto K; Itatani Y; Okada K; Sakai Y
Ann Surg Oncol; 2018 Nov; 25(12):3596-3603. PubMed ID: 30167910
[TBL] [Abstract][Full Text] [Related]
18. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.
Hayashi N; Ando Y; Gyawali B; Shimokata T; Maeda O; Fukaya M; Goto H; Nagino M; Kodera Y
Oncol Rep; 2016 Mar; 35(3):1727-31. PubMed ID: 26648321
[TBL] [Abstract][Full Text] [Related]
19. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
20. Sarcopenia is Associated with Perioperative Outcomes in Gastric Cancer Patients Undergoing Gastrectomy.
Shi B; Liu S; Chen J; Liu J; Luo Y; Long L; Lan Q; Zhang Y
Ann Nutr Metab; 2019; 75(4):213-222. PubMed ID: 31846973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
